Form 8-K - Current report:
SEC Accession No. 0001104659-24-108950
Filing Date
2024-10-16
Accepted
2024-10-16 08:00:11
Documents
15
Period of Report
2024-10-16
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2426249d1_8k.htm   iXBRL 8-K 33984
2 EXHIBIT 99.1 tm2426249d1_ex99-1.htm EX-99.1 9924
6 GRAPHIC tm2426249d1_ex99-1img001.jpg GRAPHIC 12883
  Complete submission text file 0001104659-24-108950.txt   240028

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nvax-20241016.xsd EX-101.SCH 3012
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nvax-20241016_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nvax-20241016_pre.xml EX-101.PRE 22357
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2426249d1_8k_htm.xml XML 3558
Mailing Address 700 QUINCE ORCHARD ROAD GAITHERSBURG MD 20878
Business Address 700 QUINCE ORCHARD ROAD GAITHERSBURG MD 20878 240-268-2000
NOVAVAX INC (Filer) CIK: 0001000694 (see all company filings)

EIN.: 222816046 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-26770 | Film No.: 241373308
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)